Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 236

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 236
---
 prospectus supplements, any related free writing prospectuses
and the documents incorporated by reference into this prospectus, includes all material information relating to this Resale Offering.
To the extent that any statement that we make in a prospectus supplement is inconsistent with statements made in this prospectus, the
statements made in this prospectus will be deemed modified or superseded by those made in a prospectus supplement.

Unless otherwise indicated, information contained
in this prospectus or incorporated by reference herein concerning our industry and the markets in which we operate is based on information
from independent industry and research organizations, other third-party sources (including industry publications, surveys and forecasts),
and management estimates. Management estimates are derived from publicly available information released by independent industry analysts
and third-party sources, as well as data from our internal research, and are based on assumptions made by us upon reviewing such data
and our knowledge of such industry and markets, which we believe to be reasonable. Although we believe the data from these third-party
sources is reliable, we have not independently verified any third-party information. In addition, projections, assumptions and estimates
of the future performance of the industry in which we operate and our future performance are necessarily subject to uncertainty and risk
due to a variety of factors, including those described in “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” These and other factors could cause results to differ materially from those expressed in the estimates made by
the independent parties and by us.

<div align='center'>Alt-ii</div>

[RESALE PROSPECTUS ALTERNATE PAGE] SUMMARY OF THE OFFERING

| Issuer                                                                                                                             |     | Revium Rx.                                                                                                                                   |
| Securities to be Offered by Selling Stockholders                                                                                   |     | Up to 37,625,790 Shares                                                                                                                      
 of Common Stock, consisting of (i) up to 31,253,525 shares of Common Stock, including 14,479,442 shares of Common Stock issued in            
 the Share Exchange, representing a portion of the Exchange Shares and (ii) up to an aggregate of 6,372,265 shares of Common Stock            
 issuable upon exercise of the Investor Warrants.                                                                                             |
| Common Stock outstanding before the Offering                                                                                       |     | 60,729,100 shares of Common Stock (1)                                                                                                        |
| Common Stock outstanding after the Offering (assuming                                                                              
 all of the shares underlying the units offered in the primary Offering, excluding the shares issuable upon